Transthyretin Amyloidosis (ATTR)- Market Insights, Epidemiology and Market Forecast-2027

Transthyretin Amyloidosis (ATTR)- Market Insights, Epidemiology and Market Forecast-2027

  • Pages: 120
  • Geography: Global
  • Delivery Timeline: 24 Hours
  • Publication: Aug, 2019
  • SKU: DIMI0082
  • Single User License
    20% Off
    $5000
  • Site License
    30% Off
    $8750
  • Global License
    40% Off
    $11250
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight’s 'Transthyretin Amyloidosis (ATTR)- Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Transthyretin Amyloidosis (ATTR) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Transthyretin Amyloidosis (ATTR) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered

  •  The United States
  •  EU5 (Germany, France, Italy, Spain and the United Kingdom)
  •  Japan

Study Period: 2016-2027
Transthyretin Amyloidosis (ATTR) - Disease Understanding and Treatment Algorithm
Transthyretin (earlier known as prealbumin) is an abundant, soluble, β-strand rich 55 kDa homotetramer serum protein that is responsible for the transportation of both vitamin A (via retinol-binding protein) and thyroxin throughout the body. TTR is also involved in the binding and redistribution of β-amyloid in the choroid plexus as well as in the retention of T4 in the cerebral spinal fluid (CSF). TTR may sometimes dissociate into its 127 amino acid monomeric subunits and undergo aberrant changes to form amyloidogenic intermediates. These intermediates then might self-associate to become amyloid fibrils that accumulate as amyloid deposits throughout the body, resulting in Transthyretin Amyloidosis.
Transthyretin Amyloidosis can be sub-classified as wild-type (wt) or hereditary, and the latter is then further sub-divided into familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC).
The DelveInsight Transthyretin Amyloidosis (ATTR) market report gives the thorough understanding of the Transthyretin Amyloidosis (ATTR) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Transthyretin Amyloidosis (ATTR) in the US, Europe, Japan and China.
Transthyretin Amyloidosis (ATTR) Epidemiology
The Transthyretin Amyloidosis (ATTR) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Diagnosed Prevalent Population of ATTR, Type-specific Diagnosed Prevalent Cases and Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy]scenario of Transthyretin Amyloidosis (ATTR)  in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.
According to DelveInsight, total prevalent population of ATTR in the 7 major markets ranges from approximately 19,197 cases in 2016, growing  during the study period [2016-2027].
DelveInsight also estimates higher prevalence of ATTR in the Italy with 2,044 cases in 2016 followed by France. On the other hand, United Kingdom has the lowest prevalent population in 2016.
DelveInsight estimates that the diagnosed prevalent population of ATTR will significantly increase  during the study period [2016-2027]
Hereditary transthyretin amyloidosis (hATTR) cases are segmented in to two segments which includes Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC) cases. In 2016, there were 5,201 cases of Familial Amyloid Polyneuropathy and of Familial Amyloid Cardiomyopathy in the 7MM
Transthyretin Amyloidosis (ATTR) Drug Chapters
This segment of the Transthyretin Amyloidosis (ATTR) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Current treatment options for patients with TTR amyloidosis are limited, with only symptomatic treatment and transplantation. For patients diagnosed with TTR-FAP who have a mild or moderate disease and confirmed by genetic testing and biopsy, a liver transplant is the current standard of care. However, symptomatic treatment is used to provide immediate relief.
Various mechanisms leading to TTR misfolding and fibril formation identified TTR tetramer stabilization as a rate-limiting event, leading to the development of several new pharmacologic therapies for patients with TTR-FAP. These stabilizing agents can be prescribed at an early stage in anticipation of liver transplantation, or, potentially, delaying the need for liver transplant. Drugs use in the treatment of ATTR include-Tafamidis (disease-modifying agent that kinetically stabilizes) and Diflunisal (This drug is an NSAID that stabilizes TTR tetramers in vitro, preventing disaggregation, monomer release and amyloid fibril formation by misfolded TTR monomers).
Transthyretin Amyloidosis (ATTR) Market Outlook
The Transthyretin Amyloidosis (ATTR) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
FDA has approved few drugs such as Vyndaqel (Pfizer Inc), Onpattro (Alnylam Pharmaceuticals), Tegsedi (Ionis Pharmaceuticals /Akcea Therapeutics) which are used for the treatment of Transthyretin Amyloidosis (ATTR).
Key players such as Corino Therapeutics are involved in developing therapies for Transthyretin Amyloidosis (ATTR). Expected launch of emerging therapies such as CRX-1008: Corino Therapeutics therapies will significantly impact the Transthyretin Amyloidosis (ATTR) market during the study period (2016-2027).
Transthyretin Amyloidosis (ATTR) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Transthyretin Amyloidosis (ATTR) Report Insights

  •  Patient Population
  •  Therapeutic Approaches
  •  Pipeline Analysis
  •  Market Size and Trends
  •  Market Opportunities
  •  Impact of upcoming Therapies

Transthyretin Amyloidosis (ATTR) Report Key Strengths

• 10 Years Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Sub-type Segmentation

• Key Cross Competition

• Highly Analyzed Market

• Drugs Uptake
Transthyretin Amyloidosis (ATTR) Report Assessment

  •  Current Treatment Practices
  •  Unmet Needs
  •  Pipeline Product Profiles
  •  Market Attractiveness
  •  Market Drivers and Barriers

Key Benefits

  •  This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Transthyretin Amyloidosis (ATTR)  market
  •  Organize sales and marketing efforts by identifying the best opportunities for Transthyretin Amyloidosis (ATTR)  market
  •  To understand the future market competition in the Transthyretin Amyloidosis (ATTR) market. 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83: Japan-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 84: Japan: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 85: Japan-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 86: Japan-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 87: Japan- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 88: Market Drivers
Figure 89: Market Barriers

 

1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis in 2028
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.1.1. Drug Description
12.1.2. Product Profile
12.1.3. Regulatory Milestones
12.1.4. Other Development Activities
12.1.5. Clinical Development
12.1.6. Clinical Trials Information
12.1.7. Safety and Efficacy
12.2. Inotersen: Ionis Pharmaceuticals Inc.
12.2.1. Drug Description
12.2.2. Product Profile
12.2.3. Regulatory Milestones
12.2.4. Other Development Activities
12.2.5. Clinical Development
12.2.6. Clinical Trials Information
12.2.7. Safety and Efficacy
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and Efficacy
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.3.1. Type Specific Market size of Transthyretin Amyloidosis in Germany
16.3.2. Therapy Based Market size Transthyretin Amyloidosis in Germany
16.3.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Germany
16.4. France Market Analysis
16.4.1. Type Specific Market size of Transthyretin Amyloidosis in France
16.4.2. Therapy Based Market size Transthyretin Amyloidosis in France
16.4.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in France
16.5. Spain Market Analysis
16.5.1. Type Specific Market size of Transthyretin Amyloidosis in Spain
16.5.2. Therapy Based Market size Transthyretin Amyloidosis in Spain
16.5.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Spain
16.6. Italy Market Analysis
16.6.1. Type Specific Market size of Transthyretin Amyloidosis in Italy
16.6.2. Therapy Based Market size Transthyretin Amyloidosis in Italy
16.6.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Italy
16.7. United Kingdom
16.7.1. Type Specific Market size of Transthyretin Amyloidosis in the UK
16.7.2. Therapy Based Market size Transthyretin Amyloidosis in the UK
16.7.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the UK
16.8. Japan 
16.8.1. Type Specific Market size of Transthyretin Amyloidosis in Japan
16.8.2. Therapy Based Market size Transthyretin Amyloidosis in Japan
16.8.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

 

Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Red flag symptoms of hATTR Amyloidosis
Figure 6: Clinical findings indicative of hATTR
Figure 7: Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 8: Type Specific-Diagnosed Prevalent Population of ATTR in the 7MM (2015-2028)
Figure 9: Diagnosed Prevalent Population of ATTR in the United States (2015-2028)
Figure 10: Type-specific Diagnosed Prevalent Population of hATTR in the United States (2015-2028)
Figure 11: Treatable cases of Transthyretin Amyloidosis in the United States (2015-2028)
Figure 12: Diagnosed Prevalent Population of ATTR in Germany (2015-2028)
Figure 13: Type-specific Diagnosed Prevalent Population of hATTR in Germany (2015-2028)
Figure 14: Treatable cases of Transthyretin Amyloidosis in Germany (2015-2028)
Figure 15: Diagnosed Prevalent Population of ATTR in France (2015-2028)
Figure 16: Type-specific Diagnosed Prevalent Population of hATTR in France (2015-2028)
Figure 17: Treatable cases of Transthyretin Amyloidosis in France (2015-2028)
Figure 18: Diagnosed Prevalent Population of ATTR in Italy (2015-2028)
Figure 19: Type-specific Diagnosed Prevalent Population of hATTR in Italy (2015-2028)
Figure 20: Treatable cases of Transthyretin Amyloidosis in Italy (2015-2028)
Figure 21: Diagnosed Prevalent Population of ATTR in Spain (2015-2028)
Figure 22: Type-specific Diagnosed Prevalent Population of hATTR in Spain (2015-2028)
Figure 23: Treatable cases of Transthyretin Amyloidosis in Spain (2015-2028)
Figure 24: Diagnosed Prevalent Population of ATTR in the United Kingdom (2015-2028)
Figure 25: Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom (2015-2028)
Figure 26: Treatable cases of Transthyretin Amyloidosis in the United Kingdom (2015-2028)
Figure 27: Diagnosed Prevalent Population of ATTR in Japan (2015-2028)
Figure 28: Type-specific Diagnosed Prevalent Population of hATTR in Japan (2015-2028)
Figure 29: Treatable cases of Transthyretin Amyloidosis in Japan (2015-2028)
Figure 30: ATTR related Carpal Tunnel Syndrome Surgery Cases in 7MM (2015-2028)
Figure 31: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United States (2015-2028)
Figure 32: ATTR related Carpal Tunnel Syndrome Surgery Cases in Germany (2015-2028)
Figure 33: ATTR related Carpal Tunnel Syndrome Surgery Cases in France (2015-2028)
Figure 34: ATTR related Carpal Tunnel Syndrome Surgery Cases in Italy (2015-2028)
Figure 35: ATTR related Carpal Tunnel Syndrome Surgery Cases in Spain (2015-2028)
Figure 36: ATTR related Carpal Tunnel Syndrome Surgery Cases in the United Kingdom (2015-2028)
Figure 37: ATTR related Carpal Tunnel Syndrome Surgery Cases in Japan (2015-2028)
Figure 38: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 39: Algorithm for treatment of FAP
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 42: 7MM Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 43: 7MM Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 44: 7MM Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 45: 7MM Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 46: Market Size of Transthyretin Amyloidosis in the United States, USD Millions (2015-2028)
Figure 47: United States-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 48: United States: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 49: United States-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 50: United States-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 51: United States- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 52: Market Size of Transthyretin Amyloidosis in the Germany, USD Millions (2015-2028)
Figure 53: Germany-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 54: Germany: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 55: Germany-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 56: Germany-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 57: Germany- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 58: Market Size of Transthyretin Amyloidosis in the France, USD Millions (2015-2028)
Figure 59: France-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 60: France: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 61: France-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 62: France-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 63: France- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 64: Market Size of Transthyretin Amyloidosis in the Italy, USD Millions (2015-2028)
Figure 65: Italy-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 66: Italy: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 67: Italy-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 68: Italy-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 69: Italy- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 70: Market Size of Transthyretin Amyloidosis in the Spain, USD Millions (2015-2028)
Figure 71: Spain-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 72: Spain: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 73: Spain-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 74: Spain-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 75: Spain- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 76: Market Size of Transthyretin Amyloidosis in the United Kingdom, USD Millions (2015-2028)
Figure 77: United Kingdom-Type Specific Market Size of Transthyretin Amyloidosis, USD Millions (2015-2028)
Figure 78: United Kingdom: Therapy Based Market Size of Transthyretin Amyloidosis in USD Million (2015-2028)
Figure 79: United Kingdom-Therapy Based Market Size of TTR-FAP in USD Million (2015-2028)
Figure 80: United Kingdom-Therapy Based Market Size of TTR-FAC in USD Million (2015-2028)
Figure 81: United Kingdom- Therapy Based Market Size of WT-TTR in USD Million (2015-2028)
Figure 82: Market Size of Transthyretin Amyloidosis in the Japan, USD Millions (2015-2028)
Figure 83